Moreover, defactinib monotherapy or co-administration with other agents has shown exciting therapeutic efficacy in preclinical models of ovarian cancer, PDAC, and EGFR-mutant non-small-cell lung cancer 46-48. This evidence concerns the gene EGFR and non-small cell lung carcinoma.